Anya Business Summary

Anya Biopharm Inc. (7776.TWO) is a clinical-stage biotechnology company specializing in the development of proprietary oral peptide delivery platforms, primarily targeting the high-growth metabolic and autoimmune disease markets. The company generates revenue through a hybrid model of internal drug development, strategic licensing of its platform technologies, and specialized research and testing services. Its core business segments are centered on its oral GLP-1 receptor agonist pipeline (ANY002 and ANY004) for obesity and type 2 diabetes, alongside its TNFα inhibitor program (ANY003) for inflammatory conditions. Anya utilizes advanced permeation enhancers and nanocarrier systems to convert traditionally injectable biologics into bioavailable oral formats. In the competitive landscape, Anya contends with global pharmaceutical titans such as Novo Nordisk (Rybelsus) and Eli Lilly (orforglipron), as well as specialized biotech firms like Oramed Pharmaceuticals and Structure Therapeutics. The company positions itself as a high-efficiency technology provider capable of rapid formulation and clinical translation within the competitive oral peptide niche. The leadership team at Anya Biopharm is characterized by deep institutional experience from global pharmaceutical leaders. The company is led by Co-Founder and Managing Director Siegfried Gschliesser, who brings over 20 years of experience from Sandoz, Merck, and Alvogen, and CEO Gerui Shi, who serves as General Manager and Director. Chairman Li Shu-Hui (Vicky Lee), who also serves as Chief Operating Officer, possesses a 30-year pedigree in regulatory affairs and clinical development with previous roles at GSK, Parke Davis, and Merck KGaA. The executive suite is further bolstered by SVP of Business Development Bhushan Desai, an alumnus of Biocon and Zydus Cadila. Anya was founded in 2016 and successfully listed on the Taipei Exchange (TPEx) in October 2024. Notable institutional backing includes Center Laboratories, Inc., which holds a significant 16.8% stake, and Taiwan Cooperative Venture Capital Co., Ltd., reflecting strong regional confidence in the company’s platform scalability and its potential to disrupt the injectable-dominated peptide market.